Yong Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6659509/publications.pdf

Version: 2024-02-01

117 papers	8,606 citations	53794 45 h-index	45317 90 g-index
119 all docs	119 docs citations	119 times ranked	14088 citing authors

#	Article	IF	Citations
1	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.	27.8	1,944
2	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nature Communications, 2016, 7, 11150.	12.8	577
3	Role of metabolism in cancer cell radioresistance and radiosensitization methods. Journal of Experimental and Clinical Cancer Research, 2018, 37, 87.	8.6	288
4	Cancer stem cells: A contentious hypothesis now moving forward. Cancer Letters, 2014, 344, 180-187.	7.2	217
5	Cancer stem cell in breast cancer therapeutic resistance. Cancer Treatment Reviews, 2018, 69, 152-163.	7.7	197
6	Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine. Theranostics, 2015, 5, 23-42.	10.0	184
7	RNA aptamers targeting cancer stem cell marker CD133. Cancer Letters, 2013, 330, 84-95.	7.2	157
8	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. International Journal of Biochemistry and Cell Biology, 2013, 45, 2736-2748.	2.8	155
9	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncology/Hematology, 2015, 96, 507-517.	4.4	154
10	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 2019, 19, 618.	2.6	153
11	Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. Theranostics, 2015, 5, 1083-1097.	10.0	147
12	Upregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury. Experimental Lung Research, 2013, 39, 275-282.	1.2	137
13	Exosomes and Nanoengineering: A Match Made for Precision Therapeutics. Advanced Materials, 2020, 32, e1904040.	21.0	134
14	Cancer stem cell targeted therapy: progress amid controversies. Oncotarget, 2015, 6, 44191-44206.	1.8	129
15	CD44 variant 6 is associated with prostate cancer metastasis and chemoâ€/radioresistance. Prostate, 2014, 74, 602-617.	2.3	126
16	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. Theranostics, 2020, 10, 2309-2326.	10.0	124
17	LongSAGE analysis of skeletal muscle at three prenatal stages in Tongcheng and Landrace pigs. Genome Biology, 2007, 8, R115.	9.6	123
18	MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer. Clinical and Experimental Metastasis, 2005, 22, 565-573.	3.3	111

#	Article	IF	Citations
19	Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?. Cancer Letters, 2021, 497, 100-111.	7.2	107
20	Inflammation and cancer stem cells. Cancer Letters, 2014, 345, 271-278.	7.2	105
21	Exosomes and breast cancer drug resistance. Cell Death and Disease, 2020, 11, 987.	6.3	103
22	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer and Metastasis Reviews, 2014, 33, 469-496.	5.9	100
23	The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy. Physics in Medicine and Biology, 2008, 53, 319-328.	3.0	95
24	Cancer stem cells and signaling pathways in radioresistance. Oncotarget, 2016, 7, 11002-11017.	1.8	92
25	Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach. PLoS ONE, 2015, 10, e0141876.	2.5	87
26	Genome-Wide Association Analysis of Meat Quality Traits in a Porcine Large White Ã— Minzhu Intercross Population. International Journal of Biological Sciences, 2012, 8, 580-595.	6.4	85
27	Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget, 2016, 7, 55771-55788.	1.8	85
28	Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancerâˆ†. Human Pathology, 2006, 37, 1442-1451.	2.0	77
29	Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clinical and Experimental Metastasis, 2010, 27, 557-569.	3.3	75
30	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 145, 102860.	4.4	73
31	The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer and Metastasis Reviews, 2013, 32, 535-551.	5.9	71
32	Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovascular Diabetology, 2011, 10, 69.	6.8	70
33	Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics, 2017, 7, 4071-4086.	10.0	70
34	In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147. PLoS ONE, 2012, 7, e40716.	2.5	69
35	Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecologic Oncology, 2007, 105, 695-702.	1.4	68
36	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer and Metastasis Reviews, 2012, 31, 779-791.	5.9	68

#	Article	IF	Citations
37	Urinary biomarkers in prostate cancer detection and monitoring progression. Critical Reviews in Oncology/Hematology, 2017, 118, 15-26.	4.4	64
38	Targeting MicroRNAs in Prostate Cancer Radiotherapy. Theranostics, 2017, 7, 3243-3259.	10.0	64
39	Targeted alpha therapy for cancer. Physics in Medicine and Biology, 2004, 49, 3703-3712.	3.0	62
40	Exosomes in Cancer Radioresistance. Frontiers in Oncology, 2019, 9, 869.	2.8	60
41	Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Scientific Reports, 2017, 7, 41834.	3.3	59
42	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics, 2019, 9, 4130-4140.	10.0	59
43	Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. International Immunopharmacology, 2011, 11, 449-456.	3.8	55
44	Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death and Disease, 2022, 13, 64.	6.3	50
45	Postâ€translation modification of proteins in tears. Electrophoresis, 2010, 31, 1853-1861.	2.4	49
46	Cancer stem cells in prostate cancer radioresistance. Cancer Letters, 2019, 465, 94-104.	7.2	49
47	Cancer Stem Cells in Prostate Cancer Chemoresistance. Current Cancer Drug Targets, 2014, 14, 225-240.	1.6	48
48	Loss of Annexin A1 Expression in Breast Cancer Progression. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 530-534.	1.2	46
49	Aptamer-guided extracellular vesicle theranostics in oncology. Theranostics, 2020, 10, 3849-3866.	10.0	45
50	Innovative biomarkers for prostate cancer early diagnosis and progression. Critical Reviews in Oncology/Hematology, 2010, 73, 10-22.	4.4	44
51	Practical Approaches to Kalman Filtering with Time-Correlated Measurement Errors. IEEE Transactions on Aerospace and Electronic Systems, 2012, 48, 1669-1681.	4.7	44
52	Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 23-66.	10.5	42
53	Tear Fluid Protein Biomarkers. Advances in Clinical Chemistry, 2013, 62, 151-196.	3.7	41
54	The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer. PLoS ONE, 2013, 8, e57613.	2.5	40

#	Article	IF	Citations
55	Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. Scientific Reports, 2017, 7, 5898.	3.3	40
56	In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.Aâ€•C595. Cancer Biology and Therapy, 2005, 4, 848-853.	3.4	38
57	Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Letters, 2006, 234, 176-183.	7.2	38
58	Integrated dynamic evaluation of depletion-drive performance in naturally fractured-vuggy carbonate reservoirs using DPSOâ€“FCM clustering. Fuel, 2016, 181, 996-1010.	6.4	38
59	Low Molecular Weight Heparin Ablates Lung Cancer Cisplatin-Resistance by Inducing Proteasome-Mediated ABCG2 Protein Degradation. PLoS ONE, 2012, 7, e41035.	2.5	37
60	Genome-wide Association Study of Porcine Hematological Parameters in a Large White Ã— Minzhu F2 Resource Population. International Journal of Biological Sciences, 2012, 8, 870-881.	6.4	35
61	Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PLoS ONE, 2013, 8, e74253.	2.5	35
62	The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunology, Immunotherapy, 2008, 57, 1367-1379.	4.2	34
63	CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clinical and Experimental Metastasis, 2012, 29, 1-9.	3.3	33
64	Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Therapeutic Delivery, 2012, 3, 227-244.	2.2	32
65	Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction. Coronary Artery Disease, 2012, 23, 460-468.	0.7	31
66	Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 256-263.	2.8	30
67	Proteomics for Breast Cancer Urine Biomarkers. Advances in Clinical Chemistry, 2014, 63, 123-167.	3.7	30
68	A novel double-targeted nondrug delivery system for targeting cancer stem cells. International Journal of Nanomedicine, 2016, Volume 11, 6667-6678.	6.7	30
69	Activation of the eIF2Î±/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. Redox Biology, 2021, 43, 101993.	9.0	30
70	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Letters, 2013, 329, 17-26.	7.2	29
71	Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo. BMC Cancer, 2018, 18, 1092.	2.6	29
72	The changes of microRNA expression profiles and tyrosinase related proteins in MITF knocked down melanocytes. Molecular BioSystems, 2012, 8, 2924.	2.9	28

#	Article	IF	Citations
73	A Detailed Protein-SELEX Protocol Allowing Visual Assessments of Individual Steps for a High Success Rate. Human Gene Therapy Methods, 2019, 30, 1-16.	2.1	27
74	Targeted Î±-therapy for control of micrometastatic prostate cancer. Expert Review of Anticancer Therapy, 2004, 4, 459-468.	2.4	25
75	Promising tumorâ€associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 67-101.	10.5	25
76	Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Letters, 2011, 300, 122-133.	7.2	25
77	Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin Î±-conjugate. Cancer Letters, 2004, 205, 161-171.	7.2	24
78	Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted Î± Radioimmunoconjugates. Clinical Cancer Research, 2009, 15, 865-875.	7.0	24
79	Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. Oncotarget, 2016, 7, 74269-74285.	1.8	24
80	Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model. PLoS ONE, 2011, 6, e24405.	2.5	22
81	Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted Î±-therapy with 213Bi-conjugates. International Journal of Radiation Oncology Biology Physics, 2004, 60, 896-908.	0.8	21
82	Ordovician carbonate rock matrix fractured-porous reservoirs in Tahe Oilfield, Tarim Basin, NW China. Petroleum Exploration and Development, 2014, 41, 745-753.	7.0	21
83	Proteomics discovery of radioresistant cancer biomarkers for radiotherapy. Cancer Letters, 2015, 369, 289-297.	7.2	21
84	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. Journal of the National Cancer Center, 2021, 1, 75-87.	7.4	20
85	Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biology and Therapy, 2006, 5, 386-393.	3.4	19
86	Control of prostate cancer spheroid growth using 213 Bi-labeled multiple targeted Î± radioimmunoconjugates. Prostate, 2006, 66, 1753-1767.	2.3	18
87	Aptamer-Mediated Cancer Gene Therapy. Current Gene Therapy, 2015, 15, 109-119.	2.0	18
88	Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. Translational Oncology, 2016, 9, 41-45.	3.7	18
89	THOC2 and THOC5 Regulate Stemness and Radioresistance in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2102658.	11.2	17
90	Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis . International Journal of Nanomedicine, 2020, Volume 15, 10241-10256.	6.7	16

#	Article	IF	Citations
91	A Standardized and Reproducible Urine Preparation Protocol for Cancer Biomarkers Discovery. Biomarkers in Cancer, 2014, 6, BIC.S17991.	3.6	15
92	In Vitro Targeting of NG2 Antigen by213Bi-9.2.27 Î±-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells. , 2005, 46, 4365.		13
93	CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target. Frontiers in Oncology, 2019, 9, 557.	2.8	11
94	Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats. Experimental and Therapeutic Medicine, 2013, 6, 1105-1112.	1.8	10
95	Effect of NRG-1/ErbB Signaling Intervention on the Differentiation of Bone Marrow Stromal Cells Into Sinus Nodeâ€“like Cells. Journal of Cardiovascular Pharmacology, 2014, 63, 434-440.	1.9	10
96	Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling. Analytical Biochemistry, 2016, 496, 30-34.	2.4	9
97	Virtual baseline method for Beidou attitude determination â€“ An improved long-short baseline ambiguity resolution method. Advances in Space Research, 2013, 51, 1029-1034.	2.6	8
98	Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Review of Proteomics, 2016, 13, 905-915.	3.0	8
99	In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. Cancer Control, 2019, 26, 107327481984659.	1.8	8
100	Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Nonâ€“Small Cell Lung Cancer. Translational Oncology, 2014, 7, 303-308.	3.7	7
101	CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. Experimental Cell Research, 2020, 388, 111850.	2.6	7
102	Detection of Tear Biomarkers for Future Prostate Cancer Diagnosis. Open Biomarkers Journal, 2010, 3, 26-29.	0.1	7
103	Cisplatin in 5% Ethanol Eradicates Cisplatin-Resistant Lung Tumor by Killing Lung Cancer Side Population (SP) Cells and Non-SP Cells. Frontiers in Genetics, 2013, 4, 163.	2.3	6
104	MicroRNAâ€‘146a overexpression alleviates intestinal ischemia/reperfusionâ€‘induced acute lung injury in mice. Experimental and Therapeutic Medicine, 2021, 22, 937.	1.8	5
105	A substitution within erythropoietin receptor gene D1 domain associated with litter size in Beijing Black pig, Sus scrofa. Animal Science Journal, 2011, 82, 627-632.	1.4	4
106	Data Mining in Networks of Differentially Expressed Genes during Sow Pregnancy. International Journal of Biological Sciences, 2012, 8, 548-560.	6.4	4
107	The Role of LncRNAs in the Regulation of Radiotherapy Sensitivity in Cervical Cancer. Frontiers in Oncology, 2022, 12, .	2.8	4
108	A genomeâ€wide <scp>SNP</scp> scan in a porcine <scp>L</scp>arge <scp>W</scp>hiteâ€‰Ã—â€‰<scp>M</scp>inzhu intercross population reveals a locus influencing muscle mass on chromosome 2. Animal Science Journal, 2014, 85, 969-975.	1.4	3

#	Article	IF	Citations
109	The CD44 Isoforms in Prostate Cancer Metastasis and Progression. World Journal of Cancer Research, 2013, 1, 3-14.	0.2	3
110	Intratumoral injection of cisplatin in various concentrations of ethanol for cisplatin-resistant lung tumors. Molecular and Clinical Oncology, 2014, 2, 491-496.	1.0	2
111	Erythropoietin Receptor Gene (EPOR) Polymorphisms are Associated with Sow Litter Sizes. Agricultural Sciences in China, 2011, 10, 931-937.	0.6	1
112	Abstract 1999: Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo. , 2018, , .		1
113	Relation between the Yin-cold or Yang-heat syndrome type of TCM and the EGFR gene status in patients with NSCLC. , 2014, , .		0
114	Abstract A283: PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.. , 2013, , .		0
115	Abstract 4005: CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/Î²-catenin signaling pathwaysin vitro. , 2014, , .		0
116	Abstract 2001: Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy. , 2015, , .		0
117	Abstract 2833: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo-/radio-resistanceinvitroandin vivo. , 2017, , .		0